NVCT Surges 20%

Nuvectis Pharma, Inc. (NASDAQ: NVCT ) shares are trending on Monday. 53. 05.

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing treatments for complement-related diseases and cancer. Its pipeline includes NXP100, a complement Factor B inhibitor, and cancer drug candidates NXP900 and NXP200. Portfolio Expansion Drives Rally The move higher came after Nuvectis announced a strategic portfolio expansion through a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds. The deal adds NXP100, a late-stage complement Factor B inhibitor for complement-mediated diseases, and NXP200, a paradox-breaker BRAF inhibitor for advanced cancers, to the company’s pipeline.

421 billion in milestone payments, plus royalties. 55. 66% over the past 12 months. 9% of its 52-week range.

Benzinga Edge Stock Rankings indicate that Nuvectis has a positive price trend across the short, medium and long term. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published editors. com